Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial

Objective Sodium-glucose cotransporter-2 inhibitors have been identified profound renal/cardiac protective effects in different diseases. Here, we assessed the safety and efficacy of dapagliflozin among adult patients with systemic lupus erythematosus (SLE).Methods We conducted a single-arm, open-la...

Full description

Bibliographic Details
Main Authors:	Fangfang Sun, Xiaodong Wang, Shuang Ye, Zhe Liu, Huijing Wang, Xiangyu Teng, Laurence Morel, Danting Zhang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-11-01
Series:	RMD Open
Online Access:	https://rmdopen.bmj.com/content/8/2/e002686.full

Similar Items

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.
by: Yoon-Kyung Chang, et al.
Published: (2016-01-01)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
by: Ali A. Alshamrani, et al.
Published: (2023-09-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
by: Stephan Dobner, et al.
Published: (2023-02-01)

Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes
by: Irina Claudia Anton, et al.
Published: (2022-06-01)

Effect of SGLT-2 inhibitor, dapagliflozin, on left ventricular remodeling in patients with type 2 diabetes and HFrEF
by: Qianyu Fu, et al.
Published: (2023-11-01)

Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study
by: Sabrina Kuoni, et al.
Published: (2024-02-01)

The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure
by: Alexander A. Berezin, et al.
Published: (2022-07-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
by: Yvo J.M. op den Kamp, et al.
Published: (2022-12-01)

Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2022-12-01)

Vascular Inflammation in Mouse Models of Systemic Lupus Erythematosus
by: Holly Ryan, et al.
Published: (2022-03-01)

Exercise Augments the Effect of SGLT2 Inhibitor Dapagliflozin on Experimentally Induced Diabetic Cardiomyopathy, Possible Underlying Mechanisms
by: Mamdouh Eldesoqui, et al.
Published: (2022-07-01)

The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic β-oxidation, and induces ketosis
by: Kristina Wallenius, et al.
Published: (2022-03-01)

Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study
by: Fangfang Sun, et al.
Published: (2022-06-01)

Immune Checkpoint Inhibitors and Lupus Erythematosus
by: Hans Vitzthum von Eckstaedt, et al.
Published: (2024-02-01)

Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin’s Effects in the Adrenal Gland
by: Anastasios Lymperopoulos, et al.
Published: (2021-07-01)

Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability
by: Yung‐Chih Chen, et al.
Published: (2022-01-01)

Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)
by: Justin Chan, et al.
Published: (2023-10-01)

B cell contribution of the CD4+ T cell inflammatory phenotypes in systemic lupus erythematosus
by: Seung-Chul Choi, et al.
Published: (2017-01-01)

Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
by: José C. De La Flor, et al.
Published: (2023-07-01)

Efficacy and safety of SGLT2 inhibitors in nondiabetic patients with CKD: a review of recent evidence
by: Junhao Lv, et al.
Published: (2023-04-01)

Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety
by: Angélica María Téllez Arévalo, et al.
Published: (2022-12-01)

Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity
by: Fangfang Sun, et al.
Published: (2022-07-01)

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
by: Nguyen T, et al.
Published: (2020-08-01)

EFFECT OF THE SGLT2 INHIBITOR DAPAGLIFLOZIN ON RENAL FUNCTION AND RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN ELDERLY PATIENTS WITH EARLY DIABETIC KIDNEY DISEASE
by: SUN Qian, LIU Guibo, FENG Wenjing, SONG Jie, DAI Liming, KONG Yue, XU Yinfei, CAO Caixia
Published: (2023-02-01)

The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure
by: Alexander A. Berezin, et al.
Published: (2023-02-01)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
by: Kim HC, et al.
Published: (2023-04-01)

Safety and Efficacy of Anifrolumab in Systemic Lupus Erythematosus: Systematic Review with Network Meta-analysis
by: Rawish Fatima, et al.
Published: (2023-05-01)

Safety and efficacy of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus
by: G. M. Tarasova, et al.
Published: (2021-06-01)

28 JAK-STAT inhibitors in systemic lupus erythematosus
by: Antonis Fanouriakis
Published: (2023-09-01)

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
by: Carlo Garofalo, et al.
Published: (2019-06-01)

Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study
by: Xin Wang, et al.
Published: (2023-11-01)

Efficacy and safety of baricitinib in treatment of systemic lupus erythematosus: a systematic review and meta-analysis
by: Abdallah R. Allam, et al.
Published: (2023-10-01)

Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis
by: Carlos Rafael-Vidal, et al.
Published: (2021-01-01)

The Current Concept of T[subscript H]17 Cells and Their Expanding Role in Systemic Lupus Erythematosus
by: Perry, Daniel, et al.
Published: (2011)

Experience with type I interferon inhibitor in systemic lupus erythematosus
by: Ya. A. Leineman, et al.
Published: (2022-08-01)

Safety and Efficacy of SGLT2 Inhibitors: A Multiple-Treatment Meta-Analysis of Clinical Decision Indicators
by: Vicente Martínez-Vizcaíno, et al.
Published: (2021-06-01)

Systemic lupus erythematosus presenting as lupus erythematosus tumidus and lupus nephritis: a case report
by: Meriam Hajji, et al.
Published: (2023-06-01)

SGLT2 Inhibitor—Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism
by: Batoul Dia, et al.
Published: (2023-03-01)

EFFICACY AND SAFETY OF RITUXIMAB IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A RETROSPECTIVE STUDY OF THE CASE SERIES
by: Ekaterina I. Alexeeva, et al.
Published: (2016-11-01)